Arkuda Therapeutics is focused on developing innovative therapies aimed at altering the course of neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease, and frontotemporal dementia (FTD). The company leverages its specialized expertise in lysosomal biology to gain insights into the mechanisms underlying these conditions. By understanding the role of lysosomes in cellular function and neurodegeneration, Arkuda aims to create new treatment options that can significantly improve the quality of life for individuals affected by these debilitating diseases.

The company's research pipeline reflects a commitment to translating scientific discoveries into viable therapeutic solutions. Arkuda Therapeutics is dedicated to exploring the potential of its findings in lysosomal biology to develop effective interventions for neurodegenerative disorders. Through this approach, the company seeks to bring hope to patients and their families by addressing unmet medical needs in the field of neurodegeneration, ultimately striving to change the trajectory of these diseases.

United States

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Arkuda Therapeutics

Company Details